Have your own idea? Try our Stock Screener
Canadian (TSX) Biotech Industry Analysis
UpdatedApr 08, 2026
DataAggregated Company Financials
Companies25
- 7D0.3%
- 3M-16.0%
- 1Y20.0%
- YTD-12.5%
Over the last 7 days, the Biotech industry has risen 4.1%, driven by gains from Bright Minds Biosciences of 5.2%. Meanwhile, Eupraxia Pharmaceuticals actually underperformed within the industry, shrinking 6.1% in the last week. This takes the industry's 12 month performance to a gain of 17%. As for the next few years, earnings are forecast to decline by 4.4% per annum.
Industry Valuation and Performance
Has the Canadian Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 08 Apr 2026 | CA$2.5b | CA$90.5m | -CA$254,303,627.09 | 54.5x | -9.9x | 27.8x |
| Fri, 06 Mar 2026 | CA$2.9b | CA$92.5m | -CA$239,331,352.71 | 52.8x | -11.9x | 30.9x |
| Sun, 01 Feb 2026 | CA$2.7b | CA$95.5m | -CA$241,273,724.02 | 22.6x | -11x | 27.9x |
| Tue, 30 Dec 2025 | CA$2.4b | CA$95.2m | -CA$241,010,930.73 | 22.5x | -10x | 25.3x |
| Thu, 27 Nov 2025 | CA$2.3b | CA$98.2m | -CA$230,929,662.45 | 22.3x | -9.8x | 23x |
| Sat, 25 Oct 2025 | CA$2.2b | CA$95.7m | -CA$235,974,008.87 | 25.8x | -9.4x | 23.2x |
| Mon, 22 Sep 2025 | CA$1.7b | CA$95.5m | -CA$223,369,344.47 | 26.1x | -7.8x | 18.3x |
| Wed, 20 Aug 2025 | CA$1.7b | CA$90.3m | -CA$232,498,824.01 | 20.7x | -7.2x | 18.6x |
| Fri, 18 Jul 2025 | CA$1.5b | CA$91.1m | -CA$271,685,907.47 | 22.9x | -5.5x | 16.4x |
| Sun, 15 Jun 2025 | CA$1.5b | CA$90.5m | -CA$274,802,326.95 | 22.3x | -5.3x | 16.1x |
| Tue, 13 May 2025 | CA$1.8b | CA$95.2m | -CA$310,829,223.56 | 21x | -5.7x | 18.6x |
| Thu, 10 Apr 2025 | CA$1.3b | CA$85.6m | -CA$298,155,725.39 | 20.5x | -4.4x | 15.5x |
| Sat, 08 Mar 2025 | CA$1.5b | CA$88.7m | -CA$320,458,554.69 | 21.2x | -4.8x | 17.4x |
| Mon, 03 Feb 2025 | CA$1.5b | CA$87.6m | -CA$319,160,459.25 | 24.8x | -4.8x | 17.4x |
| Wed, 01 Jan 2025 | CA$1.4b | CA$85.5m | -CA$322,565,139.85 | 15.8x | -4.5x | 16.8x |
| Fri, 29 Nov 2024 | CA$1.4b | CA$83.4m | -CA$247,584,777.56 | 8.3x | -5.6x | 16.6x |
| Sun, 27 Oct 2024 | CA$1.4b | CA$80.4m | -CA$283,730,558.61 | 8.7x | -5x | 17.7x |
| Tue, 24 Sep 2024 | CA$1.0b | CA$80.3m | -CA$281,290,558.96 | 9.1x | -3.6x | 12.5x |
| Thu, 22 Aug 2024 | CA$962.7m | CA$77.3m | -CA$287,037,852.21 | 9.5x | -3.4x | 12.5x |
| Sat, 20 Jul 2024 | CA$1.1b | CA$76.1m | -CA$339,684,577.80 | 11.3x | -3.2x | 14.3x |
| Mon, 17 Jun 2024 | CA$1.2b | CA$76.9m | -CA$340,271,341.46 | 10.9x | -3.4x | 15x |
| Wed, 15 May 2024 | CA$1.1b | CA$78.6m | -CA$345,311,677.50 | 11.8x | -3.1x | 13.6x |
| Fri, 12 Apr 2024 | CA$911.8m | CA$80.7m | -CA$299,139,762.17 | 11.9x | -3x | 11.3x |
| Sun, 10 Mar 2024 | CA$1.1b | CA$91.6m | -CA$319,845,520.80 | 10.9x | -3.5x | 12.1x |
| Tue, 06 Feb 2024 | CA$1.0b | CA$87.8m | -CA$340,044,596.86 | 9.4x | -3x | 11.6x |
| Thu, 04 Jan 2024 | CA$3.6b | CA$86.2m | -CA$515,808,070.00 | 7x | -7x | 42.1x |
| Sat, 02 Dec 2023 | CA$3.8b | CA$86.0m | -CA$542,278,469.00 | 5.2x | -6.9x | 43.7x |
| Mon, 30 Oct 2023 | CA$3.7b | CA$89.1m | -CA$538,186,417.00 | 7.4x | -6.9x | 41.7x |
| Wed, 27 Sep 2023 | CA$3.9b | CA$88.8m | -CA$530,382,953.00 | 5.7x | -7.3x | 43.8x |
| Fri, 25 Aug 2023 | CA$4.0b | CA$87.3m | -CA$510,014,920.00 | 6.4x | -7.8x | 45.4x |
| Sun, 23 Jul 2023 | CA$4.0b | CA$81.5m | -CA$516,542,925.00 | 13.4x | -7.8x | 49.5x |
| Tue, 20 Jun 2023 | CA$3.9b | CA$86.4m | -CA$543,179,028.00 | 12.6x | -7.2x | 45.4x |
| Thu, 18 May 2023 | CA$3.7b | CA$82.8m | -CA$604,425,934.00 | 11.4x | -6.1x | 44.9x |
| Sat, 15 Apr 2023 | CA$2.4b | CA$83.7m | -CA$592,548,475.00 | 12x | -4x | 28.4x |
Price to Earnings Ratio
-4x
Current Industry PE
- Investors are relatively neutral on the Canadian Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 25.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 2.6% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Canadian Healthcare industry?
| CA Market | 1.35% | |
| Healthcare | 3.38% | |
| Biotech | 0.29% | |
| Biotech | 0.29% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | CA$106.68 | 5.2% +CA$52.0m | 167.6% | PB11.7x | |
| CSCI COSCIENS Biopharma | CA$3.98 | 228.9% +CA$8.8m | 13.4% | PS1.2x | |
| NRX NurExone Biologic | CA$0.67 | 9.8% +CA$5.5m | 0% | PB30.5x | |
| SVA Sernova Biotherapeutics | CA$0.17 | 10.0% +CA$5.4m | -5.7% | PE-4.8x | |
| COV Covalon Technologies | CA$1.93 | 7.2% +CA$3.6m | -14.6% | PE54.5x |